Asosiy kontentga oʻtish
AkademScholar

Kashfiyot

Xizmatlar

Identifikatsiya

Ishlab chiquvchilar uchun

Ekotizim

Muassasalar

Nicolae Testemițanu State University of Medicine and Pharmacy

Nom variantlari: Universitatea de Medicină și Farmacie Nicolae Testemițanu din Chișinău · Universitatea de Stat de Medicină și Farmacie "Nicolae Testemițanu" · Государственный университет медицины и фармакологии имени Николая Тестемицяну

Davlat:
MD
ROR:
https://ror.org/03xww6m08
2
h-indeks
9
Iqtiboslar
16
Asarlar
15
Mualliflar
Vaqt boʻyicha

Vaqt boʻyicha tahlil

Iqtibos sharhi

Yillar boʻyicha nashrlar (ustun) va iqtiboslar (chiziq)

  • Nashrlar
  • Iqtiboslar
01345013452018201920202021202220232024202520262018: Nashrlar 2, Iqtiboslar 02019: Nashrlar 1, Iqtiboslar 02020: Nashrlar 0, Iqtiboslar 12021: Nashrlar 4, Iqtiboslar 12022: Nashrlar 3, Iqtiboslar 12023: Nashrlar 3, Iqtiboslar 52024: Nashrlar 1, Iqtiboslar 02025: Nashrlar 1, Iqtiboslar 12026: Nashrlar 1, Iqtiboslar 0

Iqtibos tarixi

013452018201920202021202220232024202520262018: Iqtiboslar 02019: Iqtiboslar 02020: Iqtiboslar 12021: Iqtiboslar 12022: Iqtiboslar 12023: Iqtiboslar 52024: Iqtiboslar 02025: Iqtiboslar 12026: Iqtiboslar 0

Nashr tarixi

013452018201920202021202220232024202520262018: Nashrlar 22019: Nashrlar 12020: Nashrlar 02021: Nashrlar 42022: Nashrlar 32023: Nashrlar 32024: Nashrlar 12025: Nashrlar 12026: Nashrlar 1

h-indeks evolyutsiyasi

Yillar boʻyicha jamlangan h-indeks

0122018201920202021202220232024202520262018: h-indeks 02019: h-indeks 02020: h-indeks 12021: h-indeks 12022: h-indeks 12023: h-indeks 22024: h-indeks 22025: h-indeks 22026: h-indeks 2

Eng koʻp iqtibos qilingan asarlar

  1. Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up20213 iqtibos
  2. HPV Vaccination and Cervical Cancer Screening Policies and Practices in 18 Countries, Territories and Entities across Eastern Europe and Central Asia20232 iqtibos
  3. Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»)20211 iqtibos
  4. The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries20231 iqtibos
  5. HIV care in Central and Eastern Europe: How close are we to the target?20180 iqtibos
  6. What is the quality of the maternal near-miss case reviews in WHO European Region? Cross-sectional study in Armenia, Georgia, Latvia, Republic of Moldova and Uzbekistan20180 iqtibos
  7. Состояние проблемы остеопороза в странах Евразийского региона20210 iqtibos
  8. Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients20210 iqtibos
  9. Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 202120220 iqtibos
  10. The third ethical commentary to COVID-19 (two years later) — vaccination, solidarity, and trust20220 iqtibos